Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Ex Input:
Dr. Nelson Teich, an oncologist and health care consultant, took the job April 17 faced with the task of aligning the ministry’s actions with the president’s view that Brazil’s economy must not be destroyed by restrictions to control spread of the virus. Teich’s predecessor, Luiz Henrique Mandetta, also had rejected the use of chloroquine, which also had been touted by U.S. President Donald Trump as a treatment. Four government ministers who spoke after Teich’s resignation defended the idea of patients being allowed to use the drug if they want to, including Economy Minister Paulo Guedes and the Cabinet chief of staff, Gen. Walter Braga Netto. Officials say almost 15,000 people have died in Brazil from COVID-19, the disease caused by the coronavirus, though some experts say the figure is significantly higher due to insufficient testing. The peak of the crisis has yet to hit Latin America’s largest nation, experts say. Gen. Eduardo Pazuello, who had no health experience until he became the Health Ministry’s No. 2 official in April, will be the interim minister until Bolsonaro chooses a replacement. Brazilian media have said that Teich’s ability to do his job had been weakened by the appointment of dozens of military personnel to jobs in the ministry. “Life is made up of choices and today I decided to leave,” Teich told journalists in capital Brasilia. He did not explain why he left the job and refused to answer questions. Braga Netto, the Cabinet chief, said Teich left the job “for personal reasons.” Bolsonaro did not comment. Teich’s resignation came one day after Bolsonaro told business leaders in a videoconference he would ease rules for using chloroquine to treat people infected with the coronavirus. Teich has frequently called use of the drug “an uncertainty,” and this week warned of its side effects. The Health Ministry previously allowed chloroquine to be used in coronavirus cases only for patients hospitalized in serious condition. At Bolsonaro’s urging, the country’s Army Chemical and Pharmaceutical Laboratory boosted chloroquine production in late March. Researchers last month reported no benefit in a large analysis of the drug or a related substance, hydroxychloroquine, in U.S. hospitals for veterans. Last month, scientists in Brazil stopped part of a study of chloroquine after heart rhythm problems developed in one quarter of people given the higher of two doses being tested. Governors who have recommended quarantine measures and refrained from touting the drug’s unproven potential said Teich’s resignation reflects Bolsonaro’s failure to manage the pandemic. Rio de Janeiro Gov. Wilson Witzel, a former ally of Bolsonaro, said “no one can do serious work with interference in ministries.” “That is why governors and mayors need to lead the pandemic crisis, and not you, Mr. President,” Witzel said on Twitter. The governor of Ceara, one of Brazil’s most hard-hit states, said Teich’s exit “brings enormous insecurity and concern.” “It is unacceptable that in the face of this serious health crisis, the focus of the government is still on political and ideological discussions. That is an affront to the nation,” Camilo Santana said. On April 16, Bolsonaro fired Teich’s predecessor, Mandetta, who had become the embodiment of challenges to the president’s opposition to governors’ quarantine recommendations and restrictions on businesses. Bolsonaro was eager to resume economic activity and warned failure to do so would cause Brazil to descend into “chaos”. Teich took office pledging to balance health care concerns and the president’s economic worries. He did not openly challenge the president’s views, but did defend stay-at-home measures. Miguel Lago, executive director of Brazil’s non-profit Institute for Health Policy Studies, which advises public health officials, said Teich wasn’t able to build his own team, didn’t have Mandetta’s political strength and wasn’t willing to violate the scientific recommendations. “He clearly had limitations,” Lago said. “He would not challenge what has been consensus among the scientific community. He would never accept the chloroquine thing that Bolsonaro wanted him to do, to recommend publicly that chloroquine was a remedy to be used in the public health system.”  Hours after Teich left the job, the Health Ministry began listing figures on chloroquine distribution as part of its main charts about government initiatives against the pandemic, alongside intensive care unit beds, personal protection equipment, tests and flu vaccines. Risk consultancy Eurasia Group analyst Filipe Gruppelli Carvalho said that the Health Ministry’s capacity for ”an effective coordinating role looks to have dropped with Mandetta’s exit,” . “Ultimately, Teich’s dismissal reinforces our view of increasing risks from the government’s poor response to the pandemic, which could contribute to a weaker presidency and decline in support for Bolsonaro in the post-pandemic phase,” he said. The newspaper Folha de S.Paulo published an editorial after Teich’s exit saying Bolsonaro is trying to “put his own survival above state policies and national interest.” “The resignation of another health minister — in less than a month and during the most serious sanitary emergency of contemporary history — exposes the downfall of a president that doesnt’t even pretend to govern the country,” the newspaper said. “As if the economic and sanitary calamities were not enough, he turned himself into a crisis to be faced.” After Teich’s resignation was announced, pot-banging protests were heard in different regions of Sao Paulo and Rio de Janeiro. _____ Associated Press writers David Biller and Diane Jeantet in Rio de Janeiro contributed to this report.

Ex Output:
Brazil’s health minister resigns after one month on the job.


Ex Input:
"Assembly Democrats want to guarantee access to abortion for New York state residents if the Supreme Court overturns the landmark Roe v. Wade decision. A bill, commonly referred to as the Reproductive Health Act, would change state law to guarantee women the choice to have or refuse an abortion or contraception if the Supreme Court reverses Roe v. Wade. Different versions of the bill have been introduced for at least seven years in the Legislature. This year’s debate over the measure included tough questions to the bill’s sponsor, Assemblymember Deborah J. Glick, from members opposed to the bill. ""So, if a baby is born intact and alive but has not yet taken its first breath, it has no rights?"" Assemblymember Steven F. McLaughlin asked. ""Is that the position you are taking?"" ""New York state law says you are alive when you begin to breathe,"" Glick said. ""That’s not me, that’s just the law."" Is Glick right? Is that the law? State abortion law Glick said her definition comes from the current state law on abortion. The definition is included in the state’s penal law, or criminal code, which defines the crime of abortion, where someone intentionally causes a pregnancy to be terminated without consent or justification. The law says a person, ""when referring to the victim of a homicide, means a human being who has been born and is alive."" So a fetus inside the womb is not considered a person, and therefore does not have rights under state law. That is why someone can legally have an abortion after being pregnant for 24 weeks to preserve the life of the mother. State health law State health law goes a step further in defining when someone is considered born. Under Public Health Law, live birth is defined as ""the complete expulsion or extraction from its mother of a product of conception, irrespective of the duration of pregnancy, which, after such separation, breathes or shows any other evidence of life such as beating of the heart, pulsation of the umbilical cord, or definite movement of voluntary muscles, whether or not the umbilical cord has been cut or the placenta is attached; each product of such a birth is considered live born."" It is up to a medical professional to determine if there is evidence of life in the infant. If the medical professional finds evidence, it is legally considered the birth of a person. ""The reality is that if they are born and alive they are a person and have full rights,"" Glick said in a phone interview. ""And that is the determination of a medical person at the time."" Our ruling Glick said during an Assembly debate that ""New York state law says you are alive when you begin to breathe."" State law says a person has been born alive when the fetus has exited the woman’s body and shows signs of life. The law specifically mentions breathing as one of the signs. But the law also mentions other evidence of life, such as a beating heart.s ."

Ex Output:
New York state law says you are alive when you begin to breathe.


Ex Input:
The company earned $728 million, or 67 cents per share, in the fourth quarter. That compared with $827 million, or 74 cents per share, in the year-earlier quarter, when Lilly took charges for asset impairments and restructuring. “Company sales were stronger than thought, but a lot of that upside came from drugs that are already off patent or about to lose patent protection,” said Edward Jones analyst Judson Clark. Excluding special items, Lilly earned 74 cents per share, matching analysts’ average forecasts, according to Thomson Reuters I/B/E/S. Shares in the company dropped 1.4 percent to 53.21, after earlier reaching their lowest in two weeks at $53.05. Lilly’s global sales fell 2 percent to $5.81 billion, but topped Wall Street forecasts of $5.46 billion. Sales would have been flat if not for the stronger dollar, which lowers the value of sales in overseas markets. Sales of Cymbalta, which lost U.S. patent protection last month, fell 38 percent to $883 million. But they came in about $100 million higher than Wall Street expected, analysts said. Lilly’s sales, earnings, and its share price, have been badly hurt since late 2011, when its Zyprexa schizophrenia drug lost U.S. patent protection. Once Lilly’s biggest product, with annual sales of $5 billion, it now has sales of only $1.5 billion. The situation worsened last month, when Cymbalta - which also had $5 billion in annual sales at its peak - began facing cheaper generics in the United States. The company’s “patent cliff” will become more daunting in March, when $1 billion-a-year osteoporosis drug Evista faces U.S. generics. “We haven’t wasted the crisis,” Chief Executive John Lechleiter said Thursday in a conference call with industry analysts. “We’re more agile, we’re leaner and I believe we’re better operators today.”  Lilly has cut more than 5,000 employees from its workforce in order to reduce annual costs by $1 billion over the last three years to deal with patent expirations on its drugs. It has also restructured itself to focus on cancer and diabetes - lucrative specialties that are two of the company’s longstanding strengths. Clark said sales of Cymbalta could eventually decline 80 percent, which has been the case for many other blockbuster medicines in recent years. He questioned whether gains for other products seen in the fourth quarter will be sustainable. Sales of many products over the quarter showed double-digit sales increases, including Lilly’s Humalog insulin, Cialis anti-impotence treatment, Forteo and Evista osteoporosis drugs, and Straterra for attention deficit disorder. But price increases in the United States accounted for much of those sales gains. The Indianapolis drugmaker is expecting a return to company sales growth next year, from increased sales of drugs that still have patent protection and from launches of new treatments for cancer and diabetes. It hopes to launch three new drugs this year: ramucirumab for stomach cancer, and dulaglutide and empagliflozin for type 2 diabetes - the most common form of the disease, which is closely linked to obesity. Although analysts have forecast annual sales of more than $650 million for ramucirumab, they are concerned the new diabetes drugs may have a hard time competing with similar drugs already on the market. The company has introduced no new products in recent years. In a recent interview, Lechleiter said it was time for Lilly “to go back on offense”, helped by a pipeline of nearly 40 medicines in mid- and late-stage studies, compared with only seven in those stages of development a decade ago.

Ex Output:

Lilly's quarterly sales largely offset Cymbalta slide.